MAPT and Alzheimer disease: Kosaraju et al. reported that the oral administration of the DPP-4 inhibitor linagliptin inhibited increases in the levels of Aβ, tau phosphorylation, neuroinflammation, and cognitive deficits in 3xTg-AD mice [24].